Zydus Life is out of favour due to its acquisition of 50% stake in Sterling Biotech. Some experts say this is a buying opportunity given the strong fundamentals of Co. KR Choksey has recommended buy for TP of ₹1439 (30% upside from CMP). In any case, short-term bounce is likely
![[IMG]](https://pbs.twimg.com/media/GV9Wrtra0AAZ07x?format=jpg&name=900x900)
![[IMG]](https://pbs.twimg.com/media/GV9WruJXwAAuih9?format=jpg&name=900x900)
| Subscribe To Our Free Newsletter |
